Patients with chronic lymphocytic leukemia (CLL) are considered in nodular partial remission (nPR) when they are in remission but bone marrow biopsies show rare nodules. The significance of the level of residual disease in nPR is not known. We studied 91 previously untreated CLL patients who were treated with fludarabine alone, fludarabine with prednisone, or fludarabine with cyclophosphamide and achieved nPR at the end of six courses. We compared bone marrow lymphoid infiltration before therapy and at the end of three and six courses of therapy as evaluated by a pathologist in retrospective fashion with that of the routine evaluation at the time of performing bone marrow biopsy. We then compared these results with those obtained by computer-aided histomorphometry in 28 patients in nPR. There was significant correlation (P Ͻ 0.05) between pathologists as well as between pathologists and histomorphometry. Upon correlation with clinical characteristics, there was significant correlation (P Ͻ 0.01) between marrow involvement before therapy and white blood cell counts (WBC), hemoglobin (Hgb), absolute lymphocyte counts, and ␤2-microglobulin (␤2-M) but none of these parameters correlated with the lymphoid infiltrate at the end of three or six courses of therapy. More importantly, lymphoid infiltration after three and six courses did not correlate with time to progression (TTP) or overall survival (OS). However, patients with Ͼ70% marrow involvement before therapy had a significantly shorter TTP (P = 0.02). All 91 patients showed similar results. However, we found reverse correlation between marrow lymphoid infiltrate at the end of three courses and OS (P = 0.01). Leukemia (2002) 16, 632-635.
Introduction
Chronic lymphocytic leukemia has a variable course and a wide range of survival time. The survival of some patients may be as short as a few months while others may live more than 25 years after diagnosis and die of unrelated causes. [1] [2] [3] [4] The variability of the clinical course and survival prediction is important for the treatment decision and follow-up. Much progress has been made over the past years in our understanding of therapy of CLL, particularly after the introduction of purine analogues. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Despite the fact that CLL is an incurable hematologic malignancy, complete remission can be achieved with conventional chemotherapy. [14] [15] [16] [17] [18] [19] In 1996, The National Cancer Institute-sponsored Working Group (NCI-WG) on CLL defined patients with complete remission (CR) and persistent bone marrow nodules as nPR. 20 The main goal of this study is to investigate the significance of the levels of the lymphoid infiltrate in nPR CLL patients and its correlation with clinical progression and overall survival. To ensure accurate esti- mation of residual disease in patients with nPR, we first compared routine morphologic evaluation with histomorphometry as determined using computer-aided measurement of residual lymphoid tissue in 28 patients with nPR. We correlated the bone marrow infiltrate with TTP and OS in this group of patients. After establishing that the routine estimation of residual disease by pathologists is comparable to that by histomorphometry, we extended our study to include an additional 64 patients (total of 91 patients) and evaluated the significance of the level of residual disease in overall outcome in this group of patients.
Materials and methods
Bone marrow biopsies from 91 previously untreated patients, seen at MD Anderson Cancer Center between 1985 and 1999, with CLL who achieved nPR were studied at the start of treatment, after three courses of chemotherapy, and after six courses of chemotherapy. Patients were selected because they were previously untreated. They were treated uniformly with minor variations that did not alter CR and OS. 12, 21 The patients were treated on three different protocols: fludarabine alone (30 mg/m 2 intravenously daily for 3 days), fludarabine with prednisone (30 mg/m 2 /d for 5 days), and fludarabine with cyclophosphamide (300-500 mg/m 2 daily for 3 days).
12,21
Specimens of the 28 patients were independently evaluated at three time intervals: at the time of obtaining the specimen (P1) as a routine evaluation, in retrospective fashion (P2) where all cases were reviewed again blindly, and by computer-aided histomorphometry through mixed (interactiveautomatic) image analysis. The histomorphometry mixed image analysis was carried out by digitizing and then quantifying the amount of lymphoid infiltrate in each image using the NIH Image program (version 1.62). All histomorphometric evaluations were performed blindly. According to the method suggested by Rywlin, 23 all specimens were classified into four groups: nodular pattern, interstitial pattern, mixed pattern and diffuse pattern. All differential counts were based on counting 500 cells on four different smears. Diagnostic criteria for CLL were based on the NCI-WG guidelines for diagnosis of CLL. 20 All the patients fulfilled these criteria. Pretreatment evaluations included medical history, physical examination, complete blood cell count and platelet count using automated cell counters; ␤2-microglobulin, creatinine, bilirubin, immunoglobulin, albumin, magnesium, sodium, potassium, chloride, transaminase, lactic dehydrogenase, glucose, and blood urea nitrogen levels were taken using automated standard biochemistry instruments. Bone marrow examination was performed on all patients. Immunoglobulin gene rearrangement analysis using Southern blot analysis was done for each patient. Immunophenotyping was performed using flow cytometry and included CD19, CD5, CD11c, CD22, CD3, CD4, CD8, CD23, CD79b, kappa, lambda, CD20, CD103, and 633 CD10. All data were retrospectively collected by chart review and entered into the leukemia database.
Statistical method
Categorical comparisons were assessed by Wilcoxon matched pairs test or Kruskal-Wallis test, and correlations between variables were assessed by Spearman correlation. Survival difference and TTP were evaluated using Kaplan-Meier plots with log-rank test and Cox proportional hazard model. Survival was measured from the time of initiating therapy, which coincides with the time of diagnosis at MD Anderson Cancer Center, and TTP was defined as time to relapse irrespective of initiating therapy or not.
Results

Patient characteristics
We first analyzed the 28 patients to establish that the estimated bone marrow level of involvement, as determined by routine morphologic evaluation, was acceptable and accurate. In this group of patients, there were 11 (39%) females and 17 (61%) males. The median age was 65.5 years (range, 47-84). The median survival was 72.2 months (range, 5-140) and the median time to progression was 67 months (range 5-129). Ten patients (36%) had a diffuse bone marrow biopsy pattern and 18 patients (64%) had a non-diffuse bone marrow biopsy pattern (9 interstitial, 2 nodular, 7 mixed) prior to treatment. After three courses of fludarabine (with or without prednisone or cyclophosphamide), 23 (82%) patients had purely nodular pattern and five (18%) patients had mixed (nodular and interstitial) pattern. All patients achieved a nodular remission after six courses of chemotherapy, which was an entry requirement for the study. The rest of the patients (63 patients) who were included in the final analysis had a similar overall profile and were treated with the same protocol.
Correlation between pathologists and histomorphometry
There was significant correlation in evaluating BM between P1 and P2 at the three different points (P Ͻ 0.0001, before therapy; P = 0.05 at three courses of chemotherapy, and P = 0.0005 at six courses of chemotherapy). Spearman rank order correlations between estimated size of lymphoid infiltrate and area of lymphoid infiltrate using morphometry was possible when the pattern was nodular. At start of treatment only two patients had nodular lymphoid infiltrate for morphometric evaluation. At three and six courses of chemotherapy, significant correlation between morphometric computerbased estimation of lymphoid infiltrate and P2 was observed (P = 0.001 and P = 0.028 respectively) (Figure 1 ).
Correlation between level of bone marrow infiltrate and various clinical characteristics
As shown in Table 1 , bone marrow (BM) lymphoid infiltrate at initial diagnosis before initiating therapy correlated with peripheral blood lymphocytes, WBC, Hgb, ␤2-M, and bone marrow lymphocytes. None of these variables (before therapy) correlated with marrow lymphoid infiltrate at three or six
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Figure 1
Correlation between computer-based and pathologist estimation of lymphoid infiltration of bone marrow. courses of chemotherapy. However, we observed inverse correlation between the number of lymph nodes sites and marrow infiltration at the end of three courses (P = 0.02) and six courses (P = 0.01). This suggests that patients would have lower levels of marrow involvement at the end of three and six courses of chemotherapy, if they had more involvement in lymph nodes at start of therapy.
Correlation between marrow infiltrate and clinical behavior
The main goal of this study was to correlate BM lymphoid infiltrate in this group of patients with clinical progression and overall survival. Upon correlation of overall survival with marrow lymphoid infiltrate using the Cox proportional hazard model, we found no significant correlation (before therapy, and at the end of three or six courses of chemotherapy). However, when we correlated TTP with the levels of marrow lymphoid infiltrate, there were significant differences in TTP between patients with Ͻ70% bone marrow involvement at the start of therapy and those with Ͼ70% involvement. Patients with Ͼ70% BM lymphoid infiltrate had significantly shorter TTP (P = 0.02) (Figure 2a ). In contrast, we found no significant correlation between lymphoid infiltrate at the end of three and six courses of therapy and TTP (Figure 2b and c) . Upon expanding our study and including the additional 63 (91 total) patients in the analysis, we obtained exactly the same results except for OS. Bone marrow lymphoid infiltrate at the end of the three course therapy correlated inversely with OS in this large number of patients (P = 0.01). Multivariate analysis with survival showed that this correlation with survival at the end of three courses was independent of Rai staging at the time of treatment, but not independent of ␤2-M.
Discussion
Achieving remission is the goal of most current therapeutic protocols of CLL. nPR is frequently seen in CLL patients. A
Figure 2
Kaplan-Meier plots showing TTP according to bone marrow lymphoid infiltrate at the start of therapy (a), at the end of three courses (b), and at the end of six courses (c).
recent report by Noy et al 23 confirmed that the residual lymphoid infiltrate in such patients represents residual disease as confirmed by polymerase chain reaction. Detection of minimal residual disease by sensitive methodology such as PCR is clinically important and relative in the management of CLL patients. 24, 25 However, the significance of the level of residual disease in nPR patients is not known. Using histology and histomorphometric studies, we studied the significance of lymphoid infiltrate in nPR CLL patients treated with fludarabine-based therapy and its correlation with various clinical parameters, overall survival, and progression. We first evaluated the accuracy of estimating BM involvement with lymphoid disease by comparing pathologists with each other and pathologists with histomorphometry. We found good correlations among pathologists and between pathologists and histomorphometry. These results demonstrated an acceptable range of interobserver variation on BM pattern of involvement and percentage of lymphoid infiltrate in evaluating bone marrow when done by different hematopathologists. Geisler et al 26 found in their study an interobserver variation concerning the presence of nodules only in 13% of the evaluated cases. The correlation between various clinical characteristics and bone marrow lymphoid infiltrate was only significant before therapy. These include peripheral blood lymphocytes, WBC, HBG, ␤2-microglobulin, and bone marrow lymphocytes. None of these parameters correlated with BM infiltrate after therapy. However, an inverse correlation was observed between the number of lymph node sites and BM infiltrate at three and six courses of therapy. Upon correlation of marrow infiltrate with overall survival using the Cox proportional hazard model, we found no significant correlation between BM level of involvement and overall survival when evaluated before therapy and at three or six courses. In previous studies hemoglobin levels were associated with a strong probability of response and ␤2-M was shown to affect the overall survival in CLL patients. 27, 28 Significant correlation was found between TTP and marrow lymphoid infiltrate (Ͻ70% vs Ͼ70%) before therapy, but we found no correlation between levels of lymphoid infiltrate at three or six courses of chemotherapy and TTP.
We expanded our study and added 63 CLL patients treated on the same protocol, who achieved nPR and who had their pathology evaluation of bone marrow reported as routine. Upon evaluating the total patient population (91 patients), all conclusions remained valid, except for finding that lymphoid infiltrate as evaluated at three courses of therapy inversely correlated with survival (P = 0.01, Cox proportional hazard model). Using multivariate analysis, we found that higher levels of bone marrow lymphoid infiltrate at three courses correlated with shorter overall survival independently of Rai staging at the time of initiating therapy (P = 0.03 for the infiltrate and P = 0.001 for Rai staging). However, when we incorporated ␤2-M in this multivariate analysis, bone marrow infiltrate at the end of three courses of therapy was no longer a predictor of survival. These findings show that levels of marrow infiltrate and ␤2-M at the time of initiating therapy are the major predictors of TTP and OS in CLL patients who achieve nPR, irrespective of their level of marrow infiltrate at the time of nPR. Further study is needed to understand the characteristics of the lymphoid cells remaining in CLL patients with nPR.
